2024
The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges.
Scala M, Fabbri C, Fusar-Poli P, Di Lorenzo G, Ferrara M, Amerio A, Fusar-Poli L, Pichiecchio A, Asteggiano C, Menchetti M, De Ronchi D, Fanelli G, Serretti A. The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges. CNS Spectrums 2024, 1-15. PMID: 39655426, DOI: 10.1017/s1092852924002268.Peer-Reviewed Original ResearchAnxiety disordersPost-traumatic stress disorderPsychedelic-assisted psychotherapyObsessive-compulsive disorderSubstance use disordersPsychotic spectrumStandard antidepressantsResearch to clinical practiceTreating moodStress disorderAddictive behaviorsPsychopharmacological researchPsychiatric conditionsPsilocybinEvidence of efficacyAnxietyMethodological limitationsDisordersMoodMethodological constraintsMethodological rigorEvidence basePotential paradigm shiftLong-term efficacyCultural stigma
2014
Treatment of Psychiatric Disorders in HIV
Ferrara M, Valero I, Moore D, Knight A, Duarte N, Atkinson J. Treatment of Psychiatric Disorders in HIV. 2014, 157-210. DOI: 10.1002/9781118339503.ch4.ChaptersPsychiatric disordersCare of HIVHealth-related qualityQuality of lifeHIV dementiaAntiretroviral therapyOverall morbidityAntiretroviral medicationsHIV infectionNeurocognitive disordersPsychopharmacological treatmentPsychiatric symptomsPsychosocial distressHIVHealth outcomesMental illnessMild formBehavioral interventionsLower likelihoodDisordersLife qualityTreatmentInterventionMedicationsMorbidity